We need to restore some 'objectivity' here..., page-10

It's just fantastic. Some people here with no investment and no financial interest in AJX know "from memory" such details like the minimum SP to achieve for the performance shares allocation.

As most of us with investment and so with a financial interest in AJX don't know such details "from memory" I'll post it for all.



As announced on the 9 October 2015, Alexium issued 3,250,000 performance rights to directors. In order to vest, milestone one and any two of the other milestones will need to be achieved from the date of despatch of the Notice until 30 June 2017 (the Period).

1. Share Price Appreciation

The price of Shares as traded on ASX must equal or exceed $1.2520, over a five- day volume weighted average closing price during the Period, being the price which is a 40% premium to the 20 day volume weighted average closing price per Share, calculated as at 17 September 2015, being the date immediately prior to this Notice.

2. Revenue of not less than $15m for the Period

The Company must achieve at least $15m in revenues during the Period.

3. Achieving Initial Product Sales in Non-Textile Areas

The Company must achieve either direct product sales revenues or licencing revenues in new product development areas outside textiles or the textile market during the Period.

4. Product Sales for Chem/Bio Protection

The Company must achieve either direct product sales revenues or licencing revenues from its RST applications on Chemical and Biological Protection ensembles during the Period.

5. US Department of Defense Contracts

The Company must enter into, directly or through a supplier, at least one significant contract with an arm or agency of the US Department of Defense during the Period in relation to products utilising FR technology.

6. Rest of the World Contracts

The Company must enter into, directly or through partners, at least two new significant contracts for the sale or licencing of FR formulations to customers located outside the United States, during the Period.

7. NYSE Markets Quotation

The Company’s ordinary shares or American Depository Receipts being quoted and trading on the New York Stock Exchange or any subsidiary exchange thereof relevant to companies the size of the Company during the Period.

8. S&P ASX 300 Index

That the Company’s ordinary shares or equivalent depositary receipts trading on the ASX are included in the S&P ASX 300 Index.